Merck to Buy Sirna for $1.1B, a 100-Percent Premium Over Yesterday's Close | GenomeWeb
NEW YORK (GenomeWeb News) — Merck today said it plans to acquire RNAi drug developer Sirna Therapeutics for around $1.1 billion in cash.
The deal is noteworthy for RNAi technology companies because Sirna, through principally a drug-discovery company, has said in the past that it would license its IP. It is not clear whether they have to date, or whether the Merck acquisition will help or hinder this goal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.